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It is often said that challenges can be viewed as opportunities in disguise. This is certainly true as 
we, the Colleges and Schools of Marshall University, Marshall Health, Cabell Huntington 
Hospital and Mountain Health Network, independently and collectively navigate the uncharted 
waters associated with COVID-19. The daily commitment and passion of our clinicians, 
scientists and educators is creatively focused on maintaining the health and wellness of our 
patients, students and colleagues. Yet, these times have also unveiled future challenges that we in 
West Virginia, the Tri-State area, and beyond will need to resolve in order to minimize 
disruption to our daily lives. Our future will be based in large part upon how well we can 
effectively work as interprofessional teams of clinicians, educators and scientists. Several 
challenges in providing timely and appropriate healthcare have been revealed with COVID-19. 
These and other currently unforeseen challenges will be the ones we will need to tackle in order 
to maintain successful patient outcomes in our urban and rural communities.  
 
It is clear we will need to continue to provide health care professionals that will serve our urban 
and rural communities in Appalachia and beyond. The health professional schools of Marshall 
University remain committed to this endeavor. We work to attract and support students in their 
education as future physicians, pharmacists, physician assistants, nurses, physical therapists, 
medical laboratory technicians, social workers, public health workers, dieticians, audiologists 
and speech-language pathologists. While we cannot clearly determine the totality of the 
economic impact of COVID-19 on our students’ abilities to pursue or complete their studies at 
this time, our current clinicians, faculty members, and friends are working to minimize 
disruptions. We have learned in the current time the importance of enhancing and providing 
stable internet connections for all our students across West Virginia and beyond. Additionally, 
this is a time for the Marshall University health science programs to collectively work with our 
communities to encourage even more students to consider professions in healthcare particularly 
as nurses, pharmacists and other health care first responders. An advantage of Marshall 
University is the number of undergraduate and graduate health professions programs that 
students can pursue and the great potential for interprofessional education and practice in our 
care of patients. 
 
A second area of concern that has been exacerbated and most likely will continue in the future is 
key drug shortages in our hospitals and community pharmacies. Drug shortages have always 
been a part of contemporary healthcare settings in hospitals and community pharmacies. The 
reason for drug shortages can include off-shore manufacturing and quality problems resulting in 
shortages in active pharmaceutical ingredients, delays, and discontinuations. For example, 
COVID-19 has resulted in disruptions of at least 156 critical drugs manufactured in China, Italy, 
India or other countries as reported by the Center for Infectious Disease Research and Policy 
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(CIDRAP) at the University of Minnesota.1 The Food and Drug Administration (FDA) is 
responsible for working closely with the manufacturers to limit or reduce the impact of these 
shortages. However, with COVID-19 we are seeing additional disruptions in the supply chain of 
essential drugs and testing reagents that may continue well beyond the current situation.2 
Hospital pharmacists and pharmacies are well acquainted with the challenges of drug shortages 
particularly intravenous fluids and injectable drugs. Hospital pharmacies often have dedicated 
staff (pharmacists and associated staff) to serve as a resource for the clinicians while managing 
and minimizing these shortages in patient care activities in their institution or healthcare system. 
These drug shortages are listed in two real-time on-line references; 1) the American Society of 
Health-System Pharmacists Drug Shortages3 and 2) the Food and Drug Administration Drug 
Shortages2.  
 
However, in the ambulatory care and community pharmacy settings, a system to minimize the 
effect of drug shortages on patient care is not as well organized in the current health care system. 
The challenge arises when the clinician writes the prescription and the patient goes to the 
community pharmacy only to find out that this specific drug is not available due to the shortage. 
The next step is the pharmacist taking time to call community pharmacies in the area to see if 
they have the drug and/or to call the physician’s office to discuss the shortage situation and 
possible therapeutic options. This comes at a cost, however, as time is lost for the pharmacist, 
physician and staff members of the clinic and pharmacy that would otherwise be used for direct 
patient care activities. Imagine a situation where one’s home is in a rural setting, one can 
certainly envision how a drug shortage of specific orally administrated drugs could impact on the 
treatment of chronic disease conditions, particularly if there is a limited number of pharmacies in 
their community.  
 
With an eye towards solving this challenge now and in the future, this is an excellent time for the 
Marshall University School of Pharmacy and the Joan C. Edwards School of Medicine to 
collaborate with community pharmacies and pharmacists in developing strategies to identify and 
minimize these drug shortages. Physicians and pharmacists in ambulatory care clinics working 
with pharmacists in their community pharmacies are excellent partners who can provide insight 
into developing strategies that can be used to solve this challenge. This solution could involve 
the development of an online searchable resource that would provide current up-to-date drug 
shortages of relevant drugs used in the clinic setting combined with the availability of these 
specific drugs in community pharmacies. This would involve two key components, 1) 
pharmacists and physicians working together to identify therapeutic options for specific drug 
shortages that could be used by their colleagues if a drug is not available and 2) a tool that could 
be used by clinic physicians and nurses as well as community pharmacists to provide the names 
of community pharmacies where the patients could find the prescribed drug. As a starting point, 
the School of Pharmacy and the School of Medicine are working together to develop the on-line 
resource for therapeutic options for drug shortages that could be used by clinicians and nurses in 
the clinics and by community pharmacists. We are also reaching out to community pharmacies to 
establish efficient and real-time approaches to collect information on the availability of drugs 
that may be in short supply in our area and eventually throughout the state. 
 
A third area of concern that we may see as a result of COVID-19 is the continued closure of 
pharmacies in rural and urban communities resulting in these areas being considered a pharmacy 
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desert. A pharmacy desert is defined as any area where patients have poor access to prescription 
medications. This lack of access can be a result of long distances to get to the pharmacy because 
of closures, limited transportation, insurance status, and lower incomes.4 It has been suggested 
that nearly 100 million Americans lack adequate access to pharmacies.5 West Virginia is no 
exception in that we have seen a continued decline in the number of pharmacies in both our 
urban and rural communities combined with long distances between our communities. One 
reason that continues to lead to the loss of community pharmacies around the country is the 
declining reimbursements that a pharmacy receives when filling the prescription order; this is 
having a significant impact on the business’ financial stability.  
 
The impact of COVID-19 on future pharmacy closures is not known at this stage. Yet there is 
concern that many of these struggling pharmacies have become frontline sources of patient care 
and information in their communities. What will happen in the future if there are shortages in 
available prescribed drugs as well as in new drugs and vaccinations? Similar declines have also 
been observed in access to patient care in rural and underserved settings. We continue to see few 
physicians choosing to work in these areas combined with the closure of community hospitals 
and health care facilities in West Virginia and the nation.6-8 Like on community pharmacies, the 
impact of COVID-19 on rural patient care is also unknown at this stage, but this will provide yet 
another strain on already a fragile health care system in rural and underserved areas. The decline 
of primary care and pharmacy services combined with the impact of COVID-19 in our rural and 
underserved communities provides another leadership opportunity for our Schools of Pharmacy 
and Medicine and for individual physicians and pharmacists to work together. Physician-
pharmacist collaborative management (PPCM) has been shown to improve the management of 
patients with chronic diseases.9 This is particularly relevant to ambulatory care clinics as recently 
approved West Virginia legislation allows pharmacists to bill for services provided that are 
within their scope of practice if these benefits would be provided for such services performed by 
other health care providers.10  
 
COVID-19 has certainly tested our educational and health care systems. Yet, we should also 
consider how this situation has provided us with openings to now advance innovative practice 
tools and sites in West Virginia. We, pharmacists and physicians, collectively need to work with 
our local governments, the West Virginia Legislature and the Governor’s Office to ensure the 
availability of patient care provided at local clinics and pharmacies. While COVID-19 has and 
continues to be a challenge to providing successful patient outcomes, this can also be the time for 
physicians and pharmacists to think creatively about new strategies for enhanced collaboration 
focused always on optimizing patient care in West Virginia and beyond.  
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